These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10685869)

  • 1. Effects of imidazoline binding site ligands on the growth and viability of clonal pancreatic beta-cells.
    Mourtada M; Elliott J; Smith SA; Morgan NG
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Feb; 361(2):146-54. PubMed ID: 10685869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the imidazoline binding site ligands, idazoxan and efaroxan, on the viability of insulin-secreting BRIN-BD11 cells.
    Gao H; Mourtada M; Morgan NG
    JOP; 2003 May; 4(3):117-24. PubMed ID: 12743417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites.
    Chan SL; Brown CA; Scarpello KE; Morgan NG
    Br J Pharmacol; 1994 Aug; 112(4):1065-70. PubMed ID: 7952865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat.
    Berdeu D; Gross R; Puech R; Loubatières-Mariani MM; Bertrand G
    Eur J Pharmacol; 1995 Feb; 275(1):91-8. PubMed ID: 7774667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: implications for stimulus-response coupling of insulin release.
    Shepherd RM; Hashmi MN; Kane C; Squires PE; Dunne MJ
    Br J Pharmacol; 1996 Nov; 119(5):911-6. PubMed ID: 8922740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imidazolines and the pancreatic B-cell. Actions and binding sites.
    Rustenbeck I; Köpp M; Ratzka P; Leupolt L; Hasselblatt A
    Ann N Y Acad Sci; 1999 Jun; 881():229-40. PubMed ID: 10415921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imidazoline/guanidinium binding sites and their relation to inhibition of K(ATP) channels in pancreatic B-cells.
    Rustenbeck I; Herrmann C; Ratzka P; Hasselblatt A
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Sep; 356(3):410-7. PubMed ID: 9303581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin secretagogues with an imidazoline structure inhibit arginine-induced secretion from isolated glucagon secretion from isolated rat islets of Langerhans.
    Mourtada M; Smith SA; Morgan NG
    Biochem Biophys Res Commun; 1997 Jul; 236(1):162-6. PubMed ID: 9223445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of locus coeruleus neurons by non-I1/I2-type imidazoline receptors: an in vivo and in vitro electrophysiological study.
    Ugedo L; Pineda J; Ruiz-Ortega JA; Martín-Ruiz R
    Br J Pharmacol; 1998 Dec; 125(8):1685-94. PubMed ID: 9886760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites.
    Brown CA; Loweth AC; Smith SA; Morgan NG
    Br J Pharmacol; 1993 Feb; 108(2):312-7. PubMed ID: 8095415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080.
    Brown CA; Chan SL; Stillings MR; Smith SA; Morgan NG
    Br J Pharmacol; 1993 Nov; 110(3):1017-22. PubMed ID: 7905338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands.
    Boronat MA; Olmos G; García-Sevilla JA
    Br J Pharmacol; 1998 Sep; 125(1):175-85. PubMed ID: 9776358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imidazolines stimulate release of insulin from RIN-5AH cells independently from imidazoline I1 and I2 receptors.
    Olmos G; Kulkarni RN; Haque M; MacDermot J
    Eur J Pharmacol; 1994 Sep; 262(1-2):41-8. PubMed ID: 7813577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous characteristics of imidazoline-induced insulin secretion.
    Rustenbeck I; Leupolt L; Kowalewski R; Hasselblatt A
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Mar; 359(3):235-42. PubMed ID: 10208311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed.
    Berdeu D; Puech R; Loubatières-Mariani MM; Bertrand G
    Eur J Pharmacol; 1996 Jul; 308(3):301-4. PubMed ID: 8858303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion.
    Mourtada M; Brown CA; Smith SA; Piercy V; Chan SL; Morgan NG
    Br J Pharmacol; 1997 Jun; 121(4):799-805. PubMed ID: 9208151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperphagic effect of novel compounds with high affinity for imidazoline I(2) binding sites.
    Polidori C; Gentili F; Pigini M; Quaglia W; Panocka I; Massi M
    Eur J Pharmacol; 2000 Mar; 392(1-2):41-9. PubMed ID: 10748271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains.
    Miralles A; Olmos G; Sastre M; Barturen F; Martin I; Garcia-Sevilla JA
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1187-97. PubMed ID: 8095548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with sigma receptors.
    Chan SL; Pallett AL; Clews J; Ramsden CA; Morgan NG
    Eur J Pharmacol; 1997 Apr; 323(2-3):241-4. PubMed ID: 9128845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The properties of imidazoline derivatives to stimulate insulin release by hamster pancreatic islets are probably due to alpha 2-adrenoceptor blockade but not to interaction with non-adrenergic idazoxan binding sites.
    Lacombe CR; Viallard VP; Paris HJ
    Diabete Metab; 1993; 19(4):381-6. PubMed ID: 7904946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.